Nitrates: new insights into old drugs
Abstract
Overview
Nitric oxide (NO), a highly unstable gas with a half-life of a few seconds, is the
most important mediator produced by endothelial cells and has several important protective
functions concerning the control of vascular tone, thrombogenesis, fibrinolysis, cell proliferation,
inflammation and endothelial permeability, which are crucial for the maintenance of an
anti-inflammatory, anti-atherogenic and anti-thrombotic state. The exogenous administration
of NO with nitrates has been proposed as possible NO exogenous sources in endothelial dysfunction
therapy and coronary artery disease because of their anti-atherosclerotic effect,
through a reduction in oxidative stress, on low-density lipoprotein (LDL) oxidation, chemotactic
molecules and growth factors, which mediate leukocytal adhesion and proliferation of
vascular smooth cells. Moreover, nitrates show a vasodilatant effect on the venous, arterial
and coronary region with a consequent reduction in preload, afterload and an improvement
in myocardial energetic metabolism. Due to these favorable effects nitrates are indicated not
only in angina pectoris, acute myocardial infarction and pulmonary hypertension or hypertension
crisis, but also in systolic and diastolic heart failure, in the prevention of ischemic and
reperfusion damage after IMA or PCI and in the prevention of post-infarctual remodeling.
Moreover, recent data concerning the protective effects of nitrates on endothelial function,
suggest their possible use in the prevention of endothelial damage and atherogenesis. (Heart
International 2007; 3: 69-77)
Keywords
Nitrates, Nitric oxide, Effects, Clinical indications
Article Information
Correspondence
Dr. Savina Nodari, Section of Cardiovascular Diseases, Dept. of Experimental and Applied Medicine, University of Brescia c/o Spedali Civili, P.zza Spedali Civili, 1, 25123 Brescia – Italy, nodari@med.unibs.it
Further Resources
Trending Topic
Cardiovascular care continues to evolve in response to increasingly complex clinical realities, where advances in intervention, electrophysiology and population health must be integrated with a more critical appraisal of long-held assumptions. Across disciplines, there is a growing recognition that improving outcomes depends not only on technological progress, but also on refining our understanding of mechanisms, […]
Cardiovascular care continues to evolve in response to increasingly complex clinical realities, where advances in intervention, electrophysiology and population health must be integrated with a more critical appraisal of long-held assumptions. Across disciplines, there is a growing recognition that improving ...
Hypertension is the leading modifiable risk factor for global cardiovascular disease, responsible for an estimated 10.8 million deaths and more than 200 million disability-adjusted life years annually.1Â Despite the availability of effective pharmacological and lifestyle interventions, prevalence continues to rise, particularly in ...
Hypertension affects over 1.4 billion adults worldwide and remains the leading modifiable risk factor for global cardiovascular (CV) morbidity and mortality. It is responsible for an estimated 10.8 million deaths annually and contributes significantly to the global burden of ischaemic heart disease, ...
Hypertension has been associated with increased cardiovascular morbidity and mortality, as well as with overall elevated all-cause mortality.1 Prevalence increases with age, affecting 28.5% of US individuals aged 20–44 years, 58.6% of those aged 45–64 years and 76.5% of those aged 65 years and older.2 In ...
Hypertension (HTN) is one of the largest contributors to cardiovascular (CV) morbidity and mortality in the USA and is estimated to affect 47% of the adult population or approximately 122 million adults older than 20 years of age.1Â Recent estimates suggest that over 40% ...
Atrial fibrillation (AF) is one of the most common arrhythmias. It affected 33.5 million people worldwide in 2010, a number that is expected to double by 2050.1Â AF prevalence increases with age, and approximately 25% of individuals aged 40 years or older will develop AF ...
Hypertension is a global health problem, with an estimated 1.13 billion individuals affected.1 Patients with hypertension, especially when resistant to conventional therapy, are at high risk of sequelae, e.g., ischaemic heart disease, haemorrhagic and ischaemic stroke, cardiac failure, peripheral vascular ...
...
...
...
...
...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
